As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Research and Development (R&D) Expenses: R&D expenses were $16.0 million for the three months ended September 30, 2024, as compared to $14.0 million for the same period in 2023. The increase was ...

If you said diabetes, you're right -- a new study finds diabetes costs $101 billion annually in diagnosis and treatment and ...

Lifecore now operates at less than 35% utilization, meaning that it can almost triple revenue with virtually no additional ...

Swiss biotech Alentis Therapeutics has secured $181.4 million, money that will be used to launch clinical trials for two ...

Digital health companies faced high advertising costs and focused on returns on investments in the third quarter.

Evotec sees a 13.3% stock rise amid reports of Triton Partners eyeing a potential buyout after acquiring a 9.99% stake in the ...

Oral phenylephrine was shown to be ineffective for treating nasal congestion over a year go. This week, the FDA took the ...

Novo Nordisk (NVO) teased some new details about a potential Ozempic successor during a call with investors Tuesday.

A day after the warning landed on semaglutide labels, Novo Nordisk CEO Lars Fruergaard Jørgensen said he is alarmed by the amount of unsafe compounded GLP-1s in the U.S. market, adding that the ...

The pharmaceutical company says data on 10 deaths and more than 100 hospitalizations comes from the FDA’s adverse event reporting database for semaglutide — the key ingredient in Ozempic and Wegovy, ...

Novo Nordisk, the maker of Ozempic, reported that compounded versions of semaglutide, the main ingredient in Ozempic and ...